Zosano Pharma Corporation (NASDAQ:ZSAN)

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company,  declared financial results for the 3rd-quarter finished September 30, 2k19, as well as recent business highlights.

Fiscal Results for the 3rd-Quarter finished September 30, 2k19
Zosano reported a net loss for the 3rd-quarter of 2k19 of $9.90M, or $0.550 for each share on a basic and diluted basis, compared with a net loss of $8.20M, or $0.680 for each share on a basic and diluted basis, for the similar quarter in 2k18.

Research and development costs for the 3rd-quarter of 2k19 were $6.50M, compared with $5.90M for the similar quarter in 2k18. The incline of $0.60M was mainly due to the scale up and technology transfer to Zosano’s contract manufacturers, and higher compensation costs, which was offset by lower clinical trial costs.

General and administrative (G&A) costs for the 3rd-quarter of 2k19 were $3.10M, compared with $2.40M in 2k18. The incline of $0.70M was mainly due to consulting and costs in preparation for commercialization.

As of September 30, 2k19, cash, cash equivalents and marketable securities were $6.50M, compared with $23.00M as of December 31, 2k18.

Leave a Reply

Your email address will not be published. Required fields are marked *